Paroxetine combined with a 5-HT(1A) receptor antagonist reversed reward deficits observed during amphetamine withdrawal in rats.
Markou
Athina
A
Department of Neuropharmacology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA. amarkou@scripps
Harrison
Amanda A
AA
Chevrette
Jessica
J
Hoyer
Daniel
D
D000342:Affective Symptoms / Q000139:chemically induced* / Q000503:physiopathology / Q000523:psychology; D000631:Aminopyridines / Q000494:pharmacology*; D000661:Amphetamine / Q000633:toxicity*; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000503:physiopathology; D004357:Drug Synergism; D007034:Hypothalamus, Posterior / Q000187:drug effects; D008297:Male; D009042:Motivation; D009638:Norepinephrine / Q000378:metabolism; D017374:Paroxetine / Q000494:pharmacology*; D010879:Piperazines / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D017208:Rats, Wistar; D012201:Reward; D012653:Self Stimulation; D058829:Serotonin 5-HT1 Receptor Antagonists; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology*; D013375:Substance Withdrawal Syndrome / Q000503:physiopathology* / Q000523:psychology
D000631:Aminopyridines; D000661:Amphetamine; D009638:Norepinephrine; D017374:Paroxetine; D010879:Piperazines; D058829:Serotonin 5-HT1 Receptor Antagonists; D017367:Selective Serotonin Reuptake Inhibitors; C087205:4-(2'-methoxyphenyl)-1-(2'-(N-(2''-pyridinyl)-4-iodobenzamido)ethyl)piperazine